Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortization - Intangibles (2016 - 2025)

Ligand Pharmaceuticals' Amortization - Intangibles history spans 11 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Amortization - Intangibles fell 2.06% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $32.7 million, down 0.79%, while the annual FY2025 figure was $32.7 million, 0.79% down from the prior year.
  • Amortization - Intangibles for Q4 2025 was $8.1 million at Ligand Pharmaceuticals, roughly flat from $8.1 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $11.8 million in Q3 2021 and bottomed at -$1.3 million in Q4 2022.
  • The 5-year median for Amortization - Intangibles is $8.3 million (2024), against an average of $7.9 million.
  • The largest annual shift saw Amortization - Intangibles tumbled 427.45% in 2021 before it skyrocketed 768.05% in 2023.
  • A 5-year view of Amortization - Intangibles shows it stood at -$1.2 million in 2021, then dropped by 7.36% to -$1.3 million in 2022, then soared by 768.05% to $8.4 million in 2023, then dropped by 1.5% to $8.3 million in 2024, then fell by 2.06% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Amortization - Intangibles are $8.1 million (Q4 2025), $8.1 million (Q3 2025), and $8.3 million (Q2 2025).